The $100m (€88m) Monroe facility is expected to produce up to 400 million tablets and capsules, 25 million vials and pre-filled syringes, and 30 million ampoules for inhaled formulations annually, at peak capacity.
Glenmark employs 168 staff at the plant – which it claims is the largest for pharmaceutical manufacture in the Charlotte region – with plans to increase headcount alongside future expansion in the area.
According to company spokesperson An Phan, Glenmark has long been focused on the US as a priority market.
“Our decision to build manufacturing in the US was part of our strategy for increasing our business and strengthening our position in the US, NC was a natural choice.
“This pro-business state welcomed our presence and provides us with solid infrastructure and a workforce ecosystem that will enable Glenmark to achieve its goals and to be a greater part of the community,” Phan told us.
East Coast attraction
According to US senator Richard Burr, high-skilled job opportunities continue to grow in the North Carolina area: “[It] is a high-growth state that continues to attract innovative companies from all over the globe.
“Our world class research universities, skilled workforce and vibrant local communities make this the perfect place to conduct cutting-edge research and invest in high-skilled jobs.”
Job growth has similarly been supported by Novo Nordisk, which announced plans to invest $64m into a finished product site in Clayton earlier this year. In addition, small molecule and API manufacturer, Cambrex, recently announced expansion plans in High Point, to meet growing demand for clinical production.
In the large molecule space, Novartis subsidiary AveXis announced a $55m manufacturing facility in Research Triangle Park over the summer, adding 200 jobs in engineering, manufacturing and quality control, and supply chain roles.
